{"id":"trastuzumab-deruxtecan-nxki","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Nausea"},{"rate":"35-45","effect":"Fatigue"},{"rate":"25-35","effect":"Vomiting"},{"rate":"20-30","effect":"Diarrhea"},{"rate":"25-35","effect":"Decreased hemoglobin/anemia"},{"rate":"1-3","effect":"Interstitial lung disease"},{"rate":"1-5","effect":"Left ventricular dysfunction"}]},"_chembl":null,"_dailymed":{"setId":"7e67e73e-ddf4-4e4d-8b50-09d7514910b6","title":"ENHERTU (FAM-TRASTUZUMAB DERUXTECAN-NXKI) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [DAIICHI SANKYO INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This drug combines trastuzumab, a monoclonal antibody targeting HER2, with deruxtecan, a potent topoisomerase I inhibitor, linked via a cleavable linker. The antibody portion recognizes and binds to HER2 on cancer cell surfaces, allowing internalization and release of the cytotoxic payload inside the cell. The topoisomerase I inhibitor then causes DNA damage and cell death, with potential bystander killing of nearby HER2-low or HER2-negative cells.","oneSentence":"Trastuzumab deruxtecan-nxki is an antibody-drug conjugate that binds HER2-positive cancer cells and delivers a topoisomerase I inhibitor payload to kill them.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:10:49.321Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HER2-positive metastatic breast cancer"},{"name":"HER2-positive gastric or gastroesophageal junction adenocarcinoma"},{"name":"HER2-low metastatic breast cancer"}]},"trialDetails":[{"nctId":"NCT04704661","phase":"PHASE1","title":"Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-08-09","conditions":"Advanced Breast Carcinoma, Advanced Colon Carcinoma, Advanced Colorectal Carcinoma","enrollment":51},{"nctId":"NCT04585958","phase":"PHASE1","title":"Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-05-21","conditions":"Metastatic Malignant Solid Neoplasm, Platinum-Resistant Ovarian High Grade Serous Adenocarcinoma, Unresectable Malignant Solid Neoplasm","enrollment":55},{"nctId":"NCT07137416","phase":"PHASE1","title":"Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-10-05","conditions":"Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma","enrollment":36},{"nctId":"NCT05372614","phase":"PHASE1","title":"Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2022-10-05","conditions":"Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm","enrollment":33},{"nctId":"NCT07012031","phase":"PHASE1, PHASE2","title":"Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-08-07","conditions":"Locally Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8","enrollment":37},{"nctId":"NCT04616560","phase":"PHASE2","title":"Trastuzumab Deruxtecan for the Treatment of HER2+ Newly Diagnosed or Recurrent Osteosarcoma","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-03-08","conditions":"Osteosarcoma, Recurrent Osteosarcoma","enrollment":77},{"nctId":"NCT06311214","phase":"PHASE2","title":"Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-03-18","conditions":"Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm","enrollment":500},{"nctId":"NCT02693535","phase":"PHASE2","title":"TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer","status":"RECRUITING","sponsor":"American Society of Clinical Oncology","startDate":"2016-03-14","conditions":"Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors","enrollment":4200},{"nctId":"NCT06364410","phase":"PHASE1","title":"Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-02-03","conditions":"Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8","enrollment":48},{"nctId":"NCT07459673","phase":"PHASE2","title":"HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2026-03-04","conditions":"Breast Cancer, HER2-positive Breast Cancer, Breast Cancer Stage IV","enrollment":60},{"nctId":"NCT04294628","phase":"PHASE1","title":"Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-09-01","conditions":"Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm","enrollment":62},{"nctId":"NCT05376878","phase":"PHASE4","title":"An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2022-12-21","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain","enrollment":10},{"nctId":"NCT07428044","phase":"PHASE2","title":"A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2026-02-13","conditions":"Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer Stage II, Non-Small Cell Lung Cancer Stage IIIA","enrollment":14},{"nctId":"NCT06058988","phase":"PHASE2","title":"Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2023-09-22","conditions":"Brain Cancer, Glioblastoma, Metastatic Cancer","enrollment":30},{"nctId":"NCT04739761","phase":"PHASE3","title":"A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-06-22","conditions":"Breast Cancer","enrollment":506},{"nctId":"NCT05408845","phase":"PHASE2","title":"Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2023-03-03","conditions":"Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage III Major Salivary Gland Cancer AJCC v8","enrollment":146},{"nctId":"NCT04553770","phase":"PHASE2","title":"Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer","status":"RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2020-10-09","conditions":"Early-stage Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Invasive Breast Cancer","enrollment":88},{"nctId":"NCT05274048","phase":"PHASE1","title":"Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients","status":"RECRUITING","sponsor":"Fox Chase Cancer Center","startDate":"2022-06-24","conditions":"Gastric Cancer, Gastrointestinal Cancer, HER2 Gene Mutation","enrollment":18},{"nctId":"NCT06533826","phase":"PHASE2","title":"TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd","status":"RECRUITING","sponsor":"Ana C Garrido-Castro, MD","startDate":"2024-10-29","conditions":"Breast Cancer, HER2-low Breast Cancer, Metastatic Breast Cancer","enrollment":357},{"nctId":"NCT06610825","phase":"PHASE2","title":"Castrate Resistant Prostate Cancer Enhertu Therapy","status":"RECRUITING","sponsor":"Washington D.C. Veterans Affairs Medical Center","startDate":"2025-03-05","conditions":"Prostate Cancer Metastatic, Prostate Cancer, CRPC","enrollment":60},{"nctId":"NCT05650879","phase":"PHASE1","title":"ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Enliven Therapeutics","startDate":"2023-03-20","conditions":"HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation","enrollment":198},{"nctId":"NCT06439693","phase":"PHASE2","title":"The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-08-08","conditions":"Breast Cancer Female, Breast Cancer, Breast Cancer Metastatic","enrollment":72},{"nctId":"NCT05868226","phase":"PHASE1","title":"PRE-I-SPY Phase I/Ib Oncology Platform Program","status":"RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2023-02-15","conditions":"HER2-positive Breast Cancer, Metastatic Cancer, Metastatic Breast Cancer","enrollment":124},{"nctId":"NCT05097599","phase":"PHASE2","title":"StrataPATH™ (Precision Indications for Approved Therapies)","status":"TERMINATED","sponsor":"Strata Oncology","startDate":"2022-04-29","conditions":"Cancer, Advanced Solid Tumor","enrollment":11}],"_emaApprovals":[],"_faersSignals":[{"count":61,"reaction":"DISEASE PROGRESSION"},{"count":60,"reaction":"METASTASES TO CENTRAL NERVOUS SYSTEM"},{"count":38,"reaction":"DIARRHOEA"},{"count":34,"reaction":"PNEUMONIA"},{"count":33,"reaction":"NAUSEA"},{"count":29,"reaction":"NEUTROPENIA"},{"count":27,"reaction":"OFF LABEL USE"},{"count":26,"reaction":"DRUG INEFFECTIVE"},{"count":26,"reaction":"FEBRILE NEUTROPENIA"},{"count":24,"reaction":"VOMITING"}],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Trastuzumab deruxtecan-nxki","genericName":"Trastuzumab deruxtecan-nxki","companyName":"Memorial Sloan Kettering Cancer Center","companyId":"memorial-sloan-kettering-cancer-center","modality":"Biologic","firstApprovalDate":"","aiSummary":"Trastuzumab deruxtecan-nxki is an antibody-drug conjugate that binds HER2-positive cancer cells and delivers a topoisomerase I inhibitor payload to kill them. Used for HER2-positive metastatic breast cancer, HER2-positive gastric or gastroesophageal junction adenocarcinoma, HER2-low metastatic breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}